Blog

In hindsight, Richard Helms remembered he had a non-painful limp in 2018. After multiple consults he was introduced to ALS, that was in 2019 and typical of the year it takes to get a diagnosis. We had mutual interests in race horses, flying, and books. Our shared curiosity in solving puzzles naturally led to a collaboration investigating ALS. Our nationwide search for a treatment (there were none) led to the creation of NDR in 2020. NDR's mission is identifying novel, under

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study will wrap up in a few months and the Phase 2 will start, it will be conducted at North Western University. We expect to validate some ALS clinical disease markers identified by Dr. Robert Naviaux’s project from patient data in these studies. Also newsworthy is the novel work NDR funded at Hesperos Inc. The project to investigate the effects o

We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found that p53 ablation protects neurons from axonal degeneration and cell death caused by C90rf72 expansion. Further, p53 ablation extends the lifespan in a mouse model of C9orf72. The literature references p53 as a driver of ALS in both familial and sporadic ALS. Reducing p53 protei

Pharmacological Characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation

Neurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS. You can read about the trial and follow our progress .

https://www.houstonmethodist.org/leading-medicine-blog/articles/2022/sep/first-biomarkers-identified-to-measure-als-disease-progression-a...

The preprint manuscript Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis by David R Borchelt (Department of Neuroscience, University of Florida, College of Medicine, Gainesville, FL) and Siobhan Ellison (Neurodegenerative Disease Research Inc., Fairfield, FL) has posted on bioRxiv. The study, conducted at The Jackson Laboratories (Bar Harbor, ME) examined the potential utility of two drugs that have indications as immune mod

NDR would like to congratulate Dr. Susanne Petri and her research team on their recent paper Altered Immunomodulatory Responses in the CX3ClL1/CX3CR1 Axis Mediated by hMSCs in an Early In Vitro SOD1G93A Model of ALS . The paper was published in November in Biomedicines 2022 and examines the effects of human mesenchymal stem/stromal cell (hMSC)-based therapy on motor neuron survival. This work provides important information in in vitro analysis of the effects of human mesench